Thioridazine

CYP2D6 substrate with narrow therapeutic index. Avoid co-administration with abiraterone.

CYP2D6 substrate with narrow therapeutic index. Avoid co-administration with abiraterone acetate.

Do not use with drugs that both prolong QT interval and are metabolized by CYP2D6.

Do not use fluoxetine with thioridazine due to QT interval prolongation risk.

Do not use fluoxetine with thioridazine due to QT prolongation risk.

Co-administration may lead to torsade de pointes-type ventricular tachycardia due to QT prolongation. Avoid concomitant use.

Do not use olanzapine and fluoxetine capsules in combination with thioridazine.

Increased plasma concentrations may increase risk of QTc prolongation and ventricular arrhythmias. Paroxetine is contraindicated in patients taking thioridazine.

Increased plasma concentrations of thioridazine may increase the risk of QTc prolongation and ventricular arrhythmias.

Concomitant use is contraindicated; see contraindications and warnings sections.

Additive QT interval prolongation effect anticipated, increasing risk of ventricular arrhythmias.

Increased plasma concentrations associated with serious and life-threatening QT prolongation and Torsades de Pointes.

Concomitant use increases risk of serotonin syndrome.

Coadministration of thioridazine has been reported to worsen the tremor in elderly patients with Parkinson's disease.

Antipsychotic that prolongs QTc interval and increases risk for Parkinsonism, NMS, and akathisia when used concomitantly with tetrabenazine.

Antipsychotic that prolongs QT interval; should be avoided with toremifene citrate or requires close monitoring.

Coadministration has been reported to worsen tremor in elderly patients with Parkinson's disease.

CYP2D6 substrate; bupropion inhibits CYP2D6 and increases thioridazine concentrations; consider dose reduction.

Bupropion inhibits CYP2D6 and can increase thioridazine concentrations; consider dose reduction of thioridazine.

CYP2D6 substrate antipsychotic. Bupropion inhibits CYP2D6, increasing thioridazine exposure. Dose reduction may be necessary.

CYP2D6 substrate antipsychotic. Bupropion inhibits CYP2D6 and can increase thioridazine concentrations. Consider dose reduction of thioridazine when used with bupropion.

CYP2D6-metabolized antipsychotic. Bupropion inhibits CYP2D6 and can increase thioridazine concentrations. Consider dose reduction.

Mixing carbamazepine suspension with liquid thioridazine results in formation of an orange rubbery precipitate. Should not be administered simultaneously.

Darifenacin may increase thioridazine exposure as it is metabolized by CYP2D6 with narrow therapeutic window. Caution should be taken when used concomitantly.

Caution when used concomitantly; darifenacin may increase exposure of thioridazine, a CYP2D6 substrate with narrow therapeutic window.

Potent CYP2D6 inhibitor may increase plasma concentration of metoprolol, decreasing cardioselectivity.

Potent CYP2D6 inhibitor may increase metoprolol plasma concentration, decreasing cardioselectivity.

Potent CYP2D6 inhibitor may increase plasma concentration of metoprolol; caution should be exercised.

Lethargy and somnolence have been reported following doses of naltrexone hydrochloride when used concomitantly with thioridazine.

Bupropion inhibits CYP2D6 and can increase thioridazine concentrations. Consider dose reduction when using with CONTRAVE.

Pindolol increases serum thioridazine levels; pindolol levels may also be increased with coadministration. Monitor therapy.

Co-administration produced additive effects on decreased alertness and impaired psychomotor performance for 2 to 4 hours. Pharmacodynamic interaction with no alteration of either drug's pharmacokinetics.